tiprankstipranks
Zhejiang Taimei Medical Technology Co Ltd Class H (HK:2576)
:2576
Hong Kong Market
Want to see HK:2576 full AI Analyst Report?

Zhejiang Taimei Medical Technology Co Ltd Class H (2576) Price & Analysis

0 Followers

2576 Stock Chart & Stats

HK$4.20
-HK$0.14(-3.49%)
At close: 4:00 PM EST
HK$4.20
-HK$0.14(-3.49%)

Bulls Say, Bears Say

Bulls Say
Revenue & Margin RecoveryA very large revenue rebound and a sustained gross margin lift to ~42% indicate improved product-market fit and better unit economics. If sustained, higher top-line scale plus stronger gross margins create a structural path to profitability and make future margin expansion more attainable.
Conservative Balance SheetLow debt and sizable equity give the company durable financial flexibility to fund operations and investments without near-term refinancing pressure. This conservatism reduces insolvency risk and supports multi-quarter execution even while earnings and cash flow recovery continue.
Improving Cash-burn TrendA material reduction in cash burn represents a positive operational trend that lowers future funding needs. Sustained improvement in cash conversion would reduce funding risk and supports a durable runway for executing growth and margin initiatives over the next several quarters.
Bears Say
Persistent Negative Cash GenerationContinued negative operating and free cash flow signals the business still consumes external capital to run operations. Over a multi-quarter horizon this elevates execution and financing risk, forcing reliance on new funding or equity dilution until operations become cash-positive.
Still Loss-making / Negative ReturnsDespite margin improvement, the company remains unprofitable and has negative ROE, meaning shareholders’ capital has yet to generate positive returns. This structural profitability gap must close to sustainably finance growth and justify reinvestment without recurrent capital raises.
Revenue VolatilityLarge swings in revenue reduce predictability of future cash flows and complicate capacity, hiring, and investment decisions. High volatility increases execution risk and raises the likelihood that recent improvements may prove cyclical rather than structural absent consistent multi-period trends.

Zhejiang Taimei Medical Technology Co Ltd Class H News

2576 FAQ

What was Zhejiang Taimei Medical Technology Co Ltd Class H’s price range in the past 12 months?
Zhejiang Taimei Medical Technology Co Ltd Class H lowest stock price was HK$3.61 and its highest was HK$7.50 in the past 12 months.
    What is Zhejiang Taimei Medical Technology Co Ltd Class H’s market cap?
    Zhejiang Taimei Medical Technology Co Ltd Class H’s market cap is HK$3.19B.
      When is Zhejiang Taimei Medical Technology Co Ltd Class H’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Zhejiang Taimei Medical Technology Co Ltd Class H’s earnings last quarter?
      Currently, no data Available
      Is Zhejiang Taimei Medical Technology Co Ltd Class H overvalued?
      According to Wall Street analysts Zhejiang Taimei Medical Technology Co Ltd Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Zhejiang Taimei Medical Technology Co Ltd Class H pay dividends?
        Zhejiang Taimei Medical Technology Co Ltd Class H does not currently pay dividends.
        What is Zhejiang Taimei Medical Technology Co Ltd Class H’s EPS estimate?
        Zhejiang Taimei Medical Technology Co Ltd Class H’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Zhejiang Taimei Medical Technology Co Ltd Class H have?
        Zhejiang Taimei Medical Technology Co Ltd Class H has 200,592,530 shares outstanding.
          What happened to Zhejiang Taimei Medical Technology Co Ltd Class H’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Zhejiang Taimei Medical Technology Co Ltd Class H?
          Currently, no hedge funds are holding shares in HK:2576
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Company Description

            Zhejiang Taimei Medical Technology Co Ltd Class H

            Zhejiang Taimei Medical Technology Co., Ltd., established in 2013 and based in Jiaxing, China, specializes in delivering sophisticated digital operational platforms specifically designed for the biopharmaceutical industry across the country. The company's core offering is TrialOS, a comprehensive digital collaboration platform that seamlessly integrates all participants throughout the drug development and research lifecycle. This ecosystem effectively links hospitals, pharmaceutical firms, external service providers, regulatory bodies, and patients, among other key industry stakeholders. Its extensive portfolio of software solutions caters to various critical aspects of clinical research and drug development. For streamlining clinical trial operations, Taimei Medical provides tools like eCooperate, which optimizes management systems and leverages big data for informed decision-making. Other related offerings include eArchives for managing master files, eCollect for electronic data capture, eCollege for training administration, eQuality for electronic audit processes, and eBalance for interactive web-based responses. Innovations such as eVisit Patient Reported Outcomes are designed to enhance patient data input and accuracy, while eTime supports project time management, and eImage facilitates medical image interpretation. Furthermore, the company supplies specialized software tailored for hospitals and Good Clinical Practice (GCP) sites. These include eTrial for managing Phase I wards, eSite and NomenCTMS for comprehensive clinical trial management at study sites, and intelligent platforms like GCP-X and Intelligent Investigator. Solutions such as eScreening assist with subject information management and deduplication, while IIT-EDC and the Investigator-Initiated Clinical Trial Management System support investigator-initiated studies and their associated data management. In the crucial domain of drug safety, the company offers robust pharmacovigilance software solutions. This includes both global and intelligent eSafety systems, alongside the SAE Manager for efficient communication and management of critical safety data during clinical trials. Complementing these, Zhejiang Taimei also develops marketing software and a variety of other digital innovation solutions.

            Zhejiang Taimei Medical Technology Co Ltd Class H (2576) Earnings & Revenues

            Similar Stocks
            Company
            Price & Change
            Follow
            Century Sage Scientific Holdings Ltd
            Aurum Pacific (China) Group Ltd.
            Sinopharm Tech Holdings Limited
            Popular Stocks